Saturday, October 2, 2021

ITP...

 



The European Medicines Agency (EMA), the European Union's drug regulator,  found a possible link between Johnson & Johnson's COVID-19 vaccine and rare cases of blood clotting in deep veins.

During a Pharmacovigilance Risk Assessment Committee meeting, the agency said it found a possible link between venous thromboembolism (VTE) and the J&J vaccine. 

The agency also recommends that immune thrombocytopenia (ITP) be listed as a side effect of the J&J vaccine and AstraZeneca's vaccine.

ITP is a bleeding disorder in which "the immune system mistakenly targets blood cells called platelets that are needed for normal blood clotting," the agency wrote.

No comments:

Post a Comment